Unique ID issued by UMIN | UMIN000017003 |
---|---|
Receipt number | R000019691 |
Scientific Title | Prospective cohort study to define the clinical and pathological features of lung cancers harboring HER2 gene aberrations. |
Date of disclosure of the study information | 2015/04/01 |
Last modified on | 2022/05/16 12:13:39 |
Prospective cohort study to define the clinical and pathological features of lung cancers harboring HER2 gene aberrations.
HER2-CS STUDY
Prospective cohort study to define the clinical and pathological features of lung cancers harboring HER2 gene aberrations.
HER2-CS STUDY
Japan |
Non-small-cell lung cancer
Pneumology |
Malignancy
NO
Define that HER2 positivity of non-small cell lung cancer
Others
Exploring the charatristics of HER2 postive non-small cell lung cancer
Develpment of the criteria of HER2 postivity in NSCLC
Observational
16 | years-old | <= |
Not applicable |
Male and Female
1. Non-small cell lung cancer with pathological confirmation
2. No radical treatment indication
3. Performance status 0-2
4. Patient with document agreement for this study
There are no special instruction regarding this section.
1000
1st name | Katsuyuki |
Middle name | |
Last name | Kiura |
Okayama University Hospital
Allergy and respiratory medicine
700-8558
2-5-1 Shikata-cho, Kita-Ku,Okayama
086-235-7227
kkiura@md.okayama-u.ac.jp
1st name | Katsuyuki |
Middle name | |
Last name | Hotta |
Okayama University Hospital
Allergy and respiratory medicine
700-8558
2-5-1 Shikata-cho, Kita-Ku,Okayama
086-235-7227
khotta@md.okayama-u.ac.jp
Okayama University
Health Labour Sciences Research Grant
Japanese Governmental office
Okayama University Hospital
2-5-2 Shikata-cho, Kita-Ku
086-235-6503
ecm6938@adm.okayama-u.ac.jp
NO
2015 | Year | 04 | Month | 01 | Day |
doi: 10.1016/j.chest.2019.01.011.
Published
https://www.sciencedirect.com/science/article/pii/S0012369219300315?via%3Dihub
1126
Of the 1,126 tumors screened, 34 (3.0%) were IHC3+, and 34 (3.0%) were IHC2+/FISH+. Among the 724 epidermal growth factor receptor wild-type tumors, 21 (2.9%) were HER2-mutant tumors, including A775-G776insYVMA (n = 15). Interestingly, the IHC3+ tumors and mutant tumors were entirely exclusive. Female patients had HER2-mutant tumors more frequently, whereas both IHC3+ and IHC2+/FISH+ tumors were detected more often in male subjects and smokers.
2022 | Year | 05 | Month | 16 | Day |
2019 | Year | 08 | Month | 01 | Day |
Patients with pathologically confirmed stage IIIB/IV or recurrent NSCLC, Eastern Cooperative Oncology Group performance status 0 to 2, were prospectively registered.
HER2 immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assays were performed to screen patients.
NA
The aim of this study was to clarify the frequency, characteristics, and outcome of HER2-positive NSCLC. HER2 was defined as positive if the tumor harbored IHC3+, IHC2+/FISH+, or exon 20 insertion mutations.
Completed
2014 | Year | 10 | Month | 31 | Day |
2015 | Year | 01 | Month | 27 | Day |
2015 | Year | 01 | Month | 27 | Day |
2019 | Year | 12 | Month | 31 | Day |
Completed
2015 | Year | 04 | Month | 01 | Day |
2022 | Year | 05 | Month | 16 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019691
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |